NCODA Logo

Olaparib (Lynparza®) Clinical Management

Written by: Katie Carter, PharmD, BCPS, Indiana University Health Download Here  Description: Olaparib is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is FDA approved as a targeted therapy for BRCA-mutated breast cancer, ovarian, pancreatic cancer, as well...

Ibrutinib (Imbruvica®) Management

Written by: Jody Agena, PharmD, MBA, BCOPDownload Here Description: Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), a key component of the B-cell receptor and cytokine receptor signaling pathway.  BTK...

Oncolytic Induced Diarrhea

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI will discuss management strategies for oncolytic medication induced diarrhea including combinations of fluid hydration therapies, antimotility agents such as loperamide, and dose...